Company CEO to discuss development at 1pm EST on 15th November 2023, at the Sidoti Virtual Investor Conference Loughborough, UK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, developer of a daily wear non-invasive glucose sensor, and digital healthcare programs today announced the UK launch of its ground-breaking approach to metabolic health and weight management by integrating continuous glucose monitoring (CGM) with its behavioral change program, Miboko, complemented by pharmaceutical interventions using GLP-1 agonists such as Ozempic, Wegovy and Mounjaro.

公司首席執(zhí)行官將于2023年11月15日在英國拉夫堡的Sidoti虛擬投資者會(huì)議上于2023年11月14日（GLOBE NEWSWIRE）于1pm EST討論開發(fā)-Nemaura Medical，日常佩戴無創(chuàng)葡萄糖傳感器的開發(fā)人員，今天，數(shù)字醫(yī)療保健計(jì)劃宣布英國通過將連續(xù)血糖監(jiān)測(cè)（CGM）與其行為改變計(jì)劃Miboko相結(jié)合，采用突破性的代謝健康和體重管理方法，輔之以使用GLP-1激動(dòng)劑（如Ozempic）的藥物干預(yù)，Wegovy和Mounjaro。

This innovative offering, featuring education, lifestyle modifications, dietary guidance, exercise goals, and cutting-edge glucose monitoring, represents a significant advancement in personalized weight loss strategies addressing the metabolic health, obesity and diabetes markets. Nemaura's program leverages the power of its world-first daily wear non-invasive CGM technology, allowing individuals to gain insights into how their body deals with glucose.

這項(xiàng)創(chuàng)新服務(wù)以教育，改變生活方式，飲食指導(dǎo)，鍛煉目標(biāo)和尖端血糖監(jiān)測(cè)為特色，代表了針對(duì)代謝健康，肥胖和糖尿病市場(chǎng)的個(gè)性化減肥策略的重大進(jìn)步。Nemaura的計(jì)劃利用了世界上首屈一指的非侵入性CGM技術(shù)的力量，使個(gè)人能夠深入了解他們的身體如何處理葡萄糖。

By using CGM for just two days per month, participants can access real-time data on how the drugs, lifestyle, diet, and exercise are impacting their blood glucose profiles, empowering them to make informed choices for sustainable improvements to quality of life. In pilot studies with the UK's National Health Service (NHS), Nemaura's program has demonstrated encouraging outcomes.

通過每月僅使用CGM兩天，參與者可以訪問有關(guān)藥物，生活方式，飲食和運(yùn)動(dòng)如何影響其血糖狀況的實(shí)時(shí)數(shù)據(jù)，使他們能夠?yàn)榭沙掷m(xù)改善生活質(zhì)量做出明智的選擇。在英國國家衛(wèi)生服務(wù)（NHS）的試點(diǎn)研究中，Nemaura的計(jì)劃顯示出令人鼓舞的結(jié)果。

Early results indicate positive responses to the integrated approach even in the absence of drug therapy using GLP-1’s, showcasing the program's potential to reshape the landscape of personalized health solutions. The integration of behaviour change programs, encompassing education on nutrition, personalized exercise regimens, and lifestyle adjustments, complements the data-driven appro.

即使在沒有使用GLP-1的藥物治療的情況下，早期結(jié)果也表明對(duì)綜合方法的積極響應(yīng)，展示了該計(jì)劃重塑個(gè)性化健康解決方案的潛力。行為改變計(jì)劃的整合，包括營養(yǎng)教育，個(gè)性化鍛煉方案和生活方式調(diào)整，補(bǔ)充了數(shù)據(jù)驅(qū)動(dòng)的APPO。

相關(guān)知識(shí)

康寶萊推出GLP
“藥王”的黃昏與GLP
GLP
亦餐GLP
大漲407%，GLP
ZOEYNUO GLP
國產(chǎn)GLP
GLP成分
4款GLP
國內(nèi)市場(chǎng)GLP

網(wǎng)址: Nemaura推出與GLP http://m.u1s5d6.cn/newsview797516.html